Investing.com - Heron Therapeuti (NASDAQ: HRTX) reported first quarter EPS of $-0.020, $0.05 better than the analyst estimate of $-0.070. Revenue for the quarter came in at $34.7M versus the consensus estimate of $32.81M.
Guidance
Heron Therapeuti sees FY 2024 revenue of $138.000M-$158.000M versus the analyst consensus of $144.900M.
Heron Therapeuti's stock price closed at $2.84. It is up 16.870% in the last 3 months and up 16.390% in the last 12 months.
Heron Therapeuti saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Heron Therapeuti's stock price’s past reactions to earnings here.
According to InvestingPro, Heron Therapeuti's Financial Health score is "fair performance".
Check out Heron Therapeuti's recent earnings performance, and Heron Therapeuti's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar